Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP

Image: Around 30% of patients with AD experience psychosis, commonly consisting of hallucinations and delusions. Credit: Gerd Altmann from Pixabay.



  • Acadia Pharmaceuticals